Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov;196(11):8214-8238.
doi: 10.1007/s12010-024-04952-0. Epub 2024 May 3.

Ammodaucus Leucotrichus Seed Extract as a Potential Therapy in Animal Models of Rheumatoid Arthritis Induced by Complete Freund Adjuvant and Chicken Cartilage Collagen

Cheima Djehiche  1 , Nadia Benzidane  1 , Hanene Djeghim  2 , Mehdi Tebboub  3 , Saad Mebrek  2 , Katia Abdelouhab  4 , Abderrahmane Baghiani  1 , Noureddine Charef  1 , Mohammed Messaoudi  5 , Chawki Bensouici  2 , Rabah Lebsir  6 , Talha Bin Emran  7 , Ali Alsalme  8 , David Cornu  9 , Mikhael Bechelany  9   10 , Lekhmici Arrar  1 , Ahmed Barhoum  11
Affiliations

Ammodaucus Leucotrichus Seed Extract as a Potential Therapy in Animal Models of Rheumatoid Arthritis Induced by Complete Freund Adjuvant and Chicken Cartilage Collagen

Cheima Djehiche et al. Appl Biochem Biotechnol. 2024 Nov.

Erratum in

Abstract

This study assessed the efficacy of an Ammodaucus leucotrichus seed extract to treat rheumatoid arthritis in rat models of this disease. Rheumatoid arthritis was induced in rats using two methods: immunization with 100 µL of Complete Freund Adjuvant (CFA) and immunization with 100 µL of a 3 mg/ml solution of type II collagen (CII) from chicken cartilage. The therapeutic potential of the extract was assessed at different doses (150, 300, and 600 mg/kg/day for 21 days in the CII-induced arthritis model and for 14 days in the CFA-induced arthritis model) and compared with methotrexate (MTX; 0.2 mg/kg for the same periods), a commonly used drug for rheumatoid arthritis treatment in humans. In both models (CII-induced arthritis and CFA-induced arthritis), walking distance, step length, intra-step distance and footprint area were improved following treatment with the A. leucotrichus seed extract (all concentrations) and MTX compared with untreated animals. Both treatments increased the serum concentration of glutathione and reduced that of complement C3, malondialdehyde and myeloperoxidase. Radiographic data and histological analysis indicated that cartilage destruction was reduced already with the lowest dose of the extract (100 mg/kg/dose) in both models. These results show the substantial antiarthritic potential of the A. leucotrichus seed extract, even at the lowest dose, suggesting that it may be a promising alternative therapy for rheumatoid arthritis and joint inflammation. They also emphasize its efficacy at various doses, providing impetus for more research on this extract as a potential therapeutic agent for arthritis.

Keywords: Ammodaucus Leucotrichus Seeds; CFA-induced Arthritis; Extract Doses; Histological Analysis; Inflammation Biomarkers; Rheumatoid Arthritis; anti-arthritic Effects; type II collagen-induced Arthritis.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethical Approval: The research protocol methodology involving experimental animals adhered to ethical guidelines outlined in the Declaration of Helsinki and The Council for International Organizations of Medical Sciences (CIOMS). Approval for these protocols was granted in alignment with ethical health research standards, as stipulated by the Algerian Executive Directive (No 10–90 JORA, dated 18 March 2004), and further complies with the provisions of Law No. 88 − 08 issued on 26 January 1988, addressing veterinary medicine activities and the safeguarding of animal health (No JORA: 004 of 27-01-1988). Consent to Participate: Participants in this research study provided informed consent by established ethical standards. Consent to Publish: Participants in this research study provided explicit consent for the publication of study findings. Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Similar articles

See all similar articles

Cited by

References

    1. Bezuidenhout, J. A., & Pretorius, E. (2020). The Central Role of Acute Phase proteins in Rheumatoid Arthritis: Involvement in Disease Autoimmunity, inflammatory responses, and the heightened risk of Cardiovascular Disease. Seminars in Thrombosis and Hemostasis, 46(4), 465–483. https://doi.org/10.1055/s-0040-1709475 Epub 2020 May 21. PMID: 32438423. - DOI - PubMed
    1. van Delft, M. A. M., & Huizinga, T. W. J. (2020). An overview of autoantibodies in rheumatoid arthritis. J Autoimmun. 110:102392. https://doi.org/10.1016/j.jaut.2019.102392 . Epub 2020 Jan 3. PMID: 31911013.
    1. Papadaki, M., Rinotas, V., Violitzi, F., Thireou, T., Panayotou, G., Samiotaki, M., & Douni, E. (2019). New insights for RANKL as a Proinflammatory Modulator in Modeled Inflammatory Arthritis. Frontiers in Immunology, 10, 97. https://doi.org/10.3389/fimmu.2019.00097 PMID: 30804932; PMCID: PMC6370657. - DOI - PubMed - PMC
    1. Smolen, J. S., Landewé, R. B. M., Bijlsma, J. W. J., Burmester, G. R., Dougados, M., Kerschbaumer, A., McInnes, I. B., Sepriano, A., van Vollenhoven, R. F., de Wit, M., Aletaha, D., Aringer, M., Askling, J., Balsa, A., Boers, M., den Broeder, A. A., Buch, M. H., Buttgereit, F., Caporali, R., Cardiel, M. H., De Cock, D., Codreanu, C., Cutolo, M., Edwards, C. J., van Eijk-Hustings, Y., Emery, P., Finckh, A., Gossec, L., Gottenberg, J. E., Hetland, M. L., Huizinga, T. W. J., Koloumas, M., Li, Z., Mariette, X., Müller-Ladner, U., Mysler, E. F., da Silva, J. A. P., Poór, G., Pope, J. E., Rubbert-Roth, A., Ruyssen-Witrand, A., Saag, K. G., Strangfeld, A., Takeuchi, T., Voshaar, M., Westhovens, R., & van der Heijde, D. (2020). EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Annals of the Rheumatic Diseases, 79(6), 685–699. https://doi.org/10.1136/annrheumdis-2019-216655 Epub 2020 Jan 22. PMID: 31969328. - DOI - PubMed
    1. Lyu, J., Wang, L., Bai, X., Du, X., Wei, J., Wang, J., Lin, Y., Chen, Z., Liu, Z., Wu, J., & Zhong, Z. (2021). Treatment of rheumatoid arthritis by serum albumin nanoparticles coated with mannose to Target neutrophils. Acs Applied Materials & Interfaces, 13(1), 266–276. https://doi.org/10.1021/acsami.0c19468 Epub 2020 Dec 30. PMID: 33379867. - DOI

MeSH terms

LinkOut - more resources